TRT basics on TikTok: separating real data from optimization hype

What did @jeremygoodmanmd actually say?

In a short TikTok, @jeremygoodmanmd offered advice on avoiding three common TRT side effects: hair loss, gynecomastia ("man boobs"), and what he called "pink problems" (likely erectile dysfunction or libido issues). For hair loss, he recommended finasteride and topical minoxidil, ideally started before hair loss begins. For gynecomastia, he advised against estrogen blockers and instead suggested lowering your testosterone dose to reduce aromatization. For "pink problems," he pointed to 5-alpha reductase inhibitors like finasteride or dutasteride.

The video is under 30 seconds, which means a lot gets flattened. Some of what he says is reasonable clinical shorthand. Some of it is genuinely wrong. And one recommendation, using finasteride for erectile function, is contradicted by the drug's own warning label.

Does the science back this up?

Partially. The hair loss recommendations are defensible. The gynecomastia advice has merit but is incomplete. The "pink problems" claim about 5-alpha reductase inhibitors is the most problematic, and it deserved a lot more nuance than it got.

Finasteride and dutasteride work by blocking the conversion of testosterone to dihydrotestosterone (DHT). DHT is a more potent androgen, and it drives androgenic alopecia. Blocking it slows hair loss, which is why these drugs are FDA-approved for that purpose (Kaufman et al., 1998, Journal of the American Academy of Dermatology). Minoxidil has solid evidence as a topical hair loss treatment as well (Olsen et al., 2002, Journal of the American Academy of Dermatology).

On gynecomastia, lowering testosterone dose to reduce aromatase conversion is a legitimate strategy. However, dismissing estrogen blockers outright ignores the fact that aromatase inhibitors are sometimes clinically appropriate when symptomatic gynecomastia is already present and dose reduction alone is insufficient (Kanakis et al., 2019, European Journal of Endocrinology).

The finasteride-for-sexual-function claim is where the wheels fall off.

What did they get wrong (or right)?

They got the hair loss section mostly right. Starting finasteride or minoxidil proactively before hair loss worsens is consistent with how dermatologists approach androgenic alopecia. No argument there.

The gynecomastia section is half-right. Dose reduction is a valid first step. But saying "don't use an estrogen blocker" as a blanket statement is too strong. Selective estrogen receptor modulators like tamoxifen have evidence for treating existing gynecomastia (Devoto et al., 2007, Fertility and Sterility), and aromatase inhibitors have a role in some clinical scenarios. Blanket avoidance of estrogen-modulating drugs is not standard practice.

The "pink problems" section is the real problem. Finasteride and dutasteride are 5-alpha reductase inhibitors, yes, but they are not treatments for erectile dysfunction or libido issues. In fact, both drugs carry FDA warnings about post-finasteride syndrome, a condition that includes persistent sexual dysfunction, including decreased libido and erectile dysfunction, even after stopping the drug (Irwig, 2012, Journal of Sexual Medicine). Recommending these drugs for "pink problems" without that context is not just incomplete, it is potentially harmful.

What should you actually know?

If you are on TRT and concerned about these side effects, here is what the evidence actually supports. Hair loss on TRT is real because exogenous testosterone raises DHT levels. Finasteride and topical minoxidil are legitimate tools, but finasteride carries sexual side effect risks that you should discuss with your prescriber before starting. It is not a consequence-free add-on.

Gynecomastia from TRT happens through aromatization of testosterone to estradiol. Dose adjustment is a reasonable first move. Estrogen modulators are not categorically off the table. Your provider should evaluate whether your estradiol levels are actually elevated before deciding on a management strategy. Reflexive estrogen suppression without labs is also a bad idea and can cause joint pain, mood issues, and cardiovascular risk.

For sexual dysfunction on TRT, the causes are varied. Low estradiol (from over-suppression), suboptimal testosterone levels, psychological factors, and vascular issues all matter. 5-alpha reductase inhibitors are not a treatment for erectile dysfunction. If anything, they carry documented risk of causing it. Talk to a provider who will actually run labs before making changes.

The bottom line

This video is a mixed bag. The hair loss advice is mostly reasonable. The gynecomastia advice oversimplifies a nuanced topic. And recommending finasteride for "pink problems" without any mention of post-finasteride syndrome risks giving someone a drug that could make their sexual function significantly worse. Short-form content on TRT management is useful for awareness, but this one crosses into territory that needs a longer conversation with a qualified provider.